Trijardy XR 2.5 mg/1

Trijardy XR 2.5 mg/1 is a combination medication containing empagliflozin, linagliptin, and metformin hydrochloride. It is designed for oral administration and is commonly used in the management of type 2 diabetes. This extended-release tablet is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.

Trijardy XR 2.5 mg/1 is primarily used in the management of type 2 diabetes. It combines three active ingredients: empagliflozin, linagliptin, and metformin hydrochloride, each contributing to the regulation of blood sugar levels. This medication is often prescribed to help control blood glucose in adults with type 2 diabetes, particularly when diet and exercise alone are not sufficient. The extended-release formulation is designed to provide a steady release of the active ingredients over time.

Common effects of Trijardy XR 2.5 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when first starting the medication. Some individuals may also experience symptoms related to low blood sugar, such as dizziness or sweating, although this is less common with this combination. It is important to monitor for any unusual symptoms and consult a healthcare provider if they persist or worsen.

Trijardy XR 2.5 mg/1 should be handled with care, especially in individuals with certain medical conditions such as kidney problems or a history of pancreatitis. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Regular monitoring of blood sugar levels is recommended to ensure the medication is working effectively and to adjust the dosage if necessary.

Trijardy XR 2.5 mg/1 may interact with other medications, including certain antibiotics, antifungal agents, and other drugs that affect kidney function. Alcohol consumption should be avoided as it can increase the risk of side effects. It is important to inform a healthcare provider about all medications being taken to avoid potential interactions.